Page Last Updated: 24 May 2023
The United Kingdom is made up of four countries: England, Scotland, Wales and Northern Ireland. All four countries left the European Union in the so-called ‘Brexit’. Collectively England, Scotland and Wales make up Great Britain. While Northern Ireland is a UK country, they are not part of Great Britain.
Northern Ireland requires, and will continue to require, European CE marking. The MDR and IVDR dates of application are mandatory in Northern Ireland, just as they are throughout the European Union.
This includes all of the requirements needed to meet CE marking, such as: compilation of the technical documentation file compliant with the EU Directives/Regulations, as applicable; appointment of a European Authorized Representative; registration of Economic Operators and devices; appointment of Person Responsible for Regulatory Compliance; market surveillance; post-market surveillance; vigilance monitoring and reporting.
Unlike the rest of the UK, Northern Ireland will not implement or recognize UKCA marking. Many of the above CE marking requirements differ from UKCA requirements.
Currently, manufacturers may place CE marked devices onto the Great Britain market, as long as they have met the requirement to appoint a UK Responsible Person and register their devices with the MHRA. That allowance was originally supposed to end on 30 June 2023; however, the MHRA extended it.
The implementation date for the new UK medical device regulations is expected to be July 2025. Additionally, the MHRA will provide a further transition period to accept CE Marking:
After the transition period ends, devices must be UKCA marked to be placed on the Great Britain market. Once this occurs, the requirements between Great Britain and Northern Ireland will more fully diverge.
For more information on the UKCA marking transition dates, please read: UK MHRA Announces New Dates for UK Regulation & CE Marking
To ensure that a hard border was not implemented between Northern Ireland and Ireland (aka Republic of Ireland), the Northern Ireland Protocol was put into place. This was to safeguard the 1998 Good Friday (Belfast) Agreement.
England, Scotland, and Wales (‘Great Britain’) all share a common landmass. While Northern Ireland is a UK country, it is not part of Great Britain.
Further, Northern Ireland is physically separate from Great Britain and instead shares its landmass with Ireland (“the island of Ireland”), which is a European Union member state. There are up to 30,000 estimated cross-border workers/students between Northern Ireland and Ireland.
Prior to Brexit, Northern Ireland and the Republic of Ireland followed the same EU trade requirements, making it easy to move goods between the two countries. However, after Brexit, suddenly trade restrictions exist under the EU-UK Trade and Cooperation Agreement, which entered into force on 1 May 2021.
Considering the historical movement of goods between Northern Ireland and Ireland, the Protocol on Ireland and Northern Ireland* was put into place.
The Protocol:
Northern Ireland is not intended as a way to avoid customs duties or circumvent UKCA marking requirements. Please see the MHRA’s guidance on moving qualifying goods from Northern Ireland to the rest of the UK for more details.
*The above is a general overview of the Protocol; there are nuances and caveats in the 181-page document not addressed here. If you have compliance concerns, we recommend reading the Protocol in full for comprehensive understanding.
NOTE: The Protocol will be replaced with the Windsor Framework. At this time, it is not expected to significantly change the medical device requirements in Northern Ireland. However, Casus will update this page as more information about the Windsor Framework is released. The EU Commission’s explanation of the Northern Ireland Protocol versus the Windsor Framework can be found: HERE
EU Authorized Representative (EU AR)
Any manufacturer not within the European Single Market must appoint a European Authorized Representative (EU AR) in order to place devices onto the market in Northern Ireland. The EU AR can be, but is not required to be, located in Northern Ireland.
The above requirement to appoint an EU AR for Northern Ireland also applies to manufacturers located in Great Britain. Northern Ireland requires CE Marking and CE Marking requires all ‘third country’ manufacturers to appoint an Authorized Representative. Therefore, Great Britain manufacturers must obtain CE marking and appoint an EU AR to place devices onto the market in Northern Ireland.
Read more about the Authorized Representative requirements here: European Authorized Representative
UK Responsible Person (UKRP)
A UK Responsible Person (UKRP) is not required to place devices onto the market in Northern Ireland. While the MHRA’s 1 January 2022 version guidance ‘Regulating medical devices in the UK’ did state it was required for certain types of devices, the 27 April 2023 update removed this requirement.
Read more about the UKRP requirements here: UK Responsible Person
Not at this time. While Great Britain manufacturers require CE Marking (and an EU Authorized Representative) to place devices onto the Northern Ireland market, Northern Ireland manufacturers are not required to obtain UKCA marking to place devices onto Great Britain. Instead, CE Marking is sufficient.
This is per the MHRA’s guidance document, which states:
“The UK Government has guaranteed unfettered access for Northern Ireland’s businesses to the rest of the UK internal market.
For medical devices, this means that any CE marked device held by a Northern Ireland business is valid for the whole of the UK market provided it falls within the definition of a qualifying “Northern Ireland good”. Therefore,
CE and CE UKNI marked devices that can be placed on the Northern Ireland market and are qualifying Northern Ireland goods, can also be placed on the Great Britain market.
In addition, if you are a Northern Ireland-based manufacturer and have already registered your device with the MHRA for the purposes of Northern Ireland, it can be placed on the Great Britain market and will not need to undergo any further registration in Great Britain.“
In some situations, yes, devices must be registered with the MHRA even if they’re only being placed onto the Northern Ireland market and not onto the rest of the UK.
Northern Ireland requires CE Marking, and therefore, registration requirements should follow the EU Directives/Regulations, as applicable. However, there are certain cases where devices being placed on the Northern Ireland market must be registered with the MHRA.
Please see the table below for more details.
Device Types to Register | |
Northern Ireland based Manufacturer | Northern Ireland manufacturers must notify the MHRA of any Class I and general IVDs (that are not for self-testing), custom-made devices and System/Procedure Packs they place onto the Northern Ireland market. |
Great Britain (GB) based Manufacturer | If the GB manufacturer appoints a Northern Ireland based EU AR, then the EU AR must register any Class I devices, general IVDs (that are not for self-testing), custom-made devices and System/Procedure Packs. The EU AR will also be responsible for registering all other device classes and types of devices with the MHRA, on the GB manufacturer’s behalf. If the GB manufacturer appoints an EU/EEA based EU AR, then the EU AR will register any Class I and general IVDs with their national Competent Authority. The GB manufacturer is then responsible for registering all other devices directly with the MHRA for the purpose of marketing in Great Britain. If the GB manufacturer is not placing devices on the Northern Ireland market, and therefore does not appoint an EU AR, then the GB manufacturer must register all its devices (all classes/ types) directly with the MHRA for the purpose of marketing in Great Britain. |
All other manufacturers with a Northern Ireland based EU AR | The Northern Ireland-based EU AR must register any Class I devices, general IVDs (that are not for self-testing), custom-made devices and System/Procedure Packs with the MHRA. For marketing in Great Britain, manufacturers must appoint a UK Responsible Person (UKRP) and the UKRP will register all devices on the manufacturer’s behalf. The UKRP may be the same entity as the Northern Ireland EU AR, if they agree contractually to take on both roles. |
All other manufacturers | All custom-made devices being placed on the Northern Ireland market must be notified to the MHRA within 28 days of being made available on the Northern Ireland market. For marketing in Great Britain, manufacturers must appoint a UK Responsible Person (UKRP) and the UKRP will register all devices on the manufacturer’s behalf. |
UKNI marking is only required in the following situation:
A manufacturer placing devices onto the Northern Ireland market chooses a UK-based conformity assessment body (aka ‘UK Notified Body’) to issue CE Marking. In this situation, manufacturers would apply both the CE marking and UKNI marking to the device. UKNI marking is never issued on its own, without CE marking.
The reason for UKNI marking, is that there are still some UK-based conformity assessment bodies accredited to issue CE Marking, from when the UK was still an EU member state. However, while they could apply to do so in the future, no UK Notified Bodies are currently accredited to issue CE Marking to the MDR/IVDR. Currently, they are all only able to issue CE marking under the Directives .
UKNI does not apply in the following scenarios:
In Short
If you do not use a UK Notified Body for CE Marking, then UKNI marking does not apply to you. Considering none of the UK Notified Bodies are designated under the MDR/IVDR, the likelihood of needing UNKI marking is low.
Generally, no. As mentioned in the above UKNI marking section, UKNI marking is rarely applicable.
What is ultimately needed to place devices onto markets is:
Great Britain
Northern Ireland
You may have seen or read updates regarding this route, which became operational as of January 1, 2022.
The Northern Ireland MHRA Authorised Route (NIMAR) is a special access route for medicines, not medical devices. It is to help ensure that people in Northern Ireland continue to have access to prescription-only medicines, if their clinical needs cannot be met through other authorized products or existing regulatory routes. i.e., it provides access to medicines that are unlicensed in Northern Ireland, but which are licensed in Great Britain.
This process is tightly controlled and, as mentioned above, is an option available for medicines and not medical devices.
The below is a brief overview of differences. Please read the above sections for more details.
Great Britain | Northern Ireland | |
Conformity Assessment | CE Marking (allowed until transition period ends between July 2028-2030, depending on the type of device) UKCA marking (mandatory as of 2028-2030, after the CE Marking transition period ends) | CE Marking In some rare cases, UKNI marking |
In-country representative | UK Responsible Person (UKRP) | European Authorized Representative (EU AR) A UKRP is not required for manufacturers located in Northern Ireland |
Registration | All manufacturers and devices must be registered with the MHRA. Registration conducted by the UKRP, if the manufacturer is located outside of the UK. | Per CE Marking requirements. May also include notifying the MHRA of some devices, e.g., custom-made devices placed onto the Northern Ireland market |
Labeling | CE marking / UKCA marking, as applicable. UKCA marking should not be affixed unless the device has been UKCA marked. UK Responsible Person – only required on labeling if the device is UKCA marked. | CE Marking In some rare cases, UKNI marking EU Authorized Representative, if the manufacturer is located outside of Northern Ireland or the EU/EEA |